Skip to content
Evigrade
MajorClass Ic antiarrhythmic with beta-blocking activity×Atypical antipsychotic – indole derivative

Updated · Methodology

Mechanism

Ziprasidone causes mild to moderate, dose-dependent QT prolongation (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Propafenone, a class IC antiarrhythmic with weak beta-blocking activity, prolongs the PR interval and widens the QRS complex. According to the US label, it may also prolong QT, but QRS widening makes QT changes difficult to interpret (propafenone SmPC, AEMPS, and label, US Food and Drug Administration, FDA). No studies have looked at ziprasidone together with other QT-prolonging drugs, and an additive effect cannot be excluded (ziprasidone SmPC, AEMPS). Propafenone has not been extensively studied with such drugs either (propafenone label, FDA). Propafenone may raise the levels of drugs that CYP2D6 metabolises. But CYP2D6 is not among the pathways of ziprasidone metabolism, and about two thirds of ziprasidone metabolism does not involve cytochrome P450 enzymes (propafenone and ziprasidone SmPCs, AEMPS). CYP2D6 and CYP3A4 metabolise propafenone, and ziprasidone itself is unlikely to change the metabolism of their substrates to a clinically relevant degree. The documents give no data on how one drug changes the level of the other (ziprasidone and propafenone SmPCs, AEMPS).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Palpitations, vertigo, fainting or seizures during ziprasidone treatment may signal a malignant arrhythmia (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Propafenone can cause new or worse arrhythmias, including ventricular tachycardia, ventricular fibrillation and torsade de pointes. It can also cause heart block and a slow heart rate (propafenone SmPC, AEMPS, and label, US Food and Drug Administration, FDA). In people taking QT-prolonging drugs, a slow heart rate, low potassium or magnesium, and the use of other such drugs raise the risk of torsade de pointes and sudden death (ziprasidone label, FDA).

Management

Avoid the combination. The Spanish ziprasidone summaries of product characteristics (SmPCs) contraindicate ziprasidone with QT-prolonging drugs and give such drugs as examples. Propafenone is not among them (ziprasidone SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish propafenone SmPC mentions QT prolongation only as a reason to lower the dose or interrupt treatment. The US label says propafenone may prolong QT, but QRS widening makes this hard to assess (propafenone SmPC, AEMPS, and label, US Food and Drug Administration, FDA). For this reason, the editors do not classify the combination as contraindicated. The US propafenone label says to avoid propafenone with other QT-prolonging drugs (propafenone label, FDA). Both ziprasidone documents state that ziprasidone prolongs QT, and its US label also says to avoid ziprasidone in people with a history of cardiac arrhythmias (ziprasidone SmPC, AEMPS, and label, FDA). Ziprasidone is contraindicated in known QT prolongation and decompensated heart failure. Use it with caution in marked bradycardia, and correct low potassium and magnesium before starting it (ziprasidone SmPC, AEMPS). Propafenone is contraindicated in severe symptomatic bradycardia, marked electrolyte imbalance and uncontrolled congestive heart failure with a left ventricular ejection fraction below 35% (propafenone SmPC, AEMPS). Record an electrocardiogram (ECG) before and during propafenone treatment. If the QRS complex or the heart-rate-corrected QT interval (QTc) lengthens, or second- or third-degree atrioventricular block appears, lower the dose or interrupt treatment until the ECG returns to normal (propafenone SmPC, AEMPS). If palpitations, vertigo, fainting or seizures appear during ziprasidone treatment, carry out a cardiac assessment including an ECG. If QTc exceeds 500 ms, the SmPC recommends interrupting ziprasidone (ziprasidone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Propafenone

Other interactions with Ziprasidone